Drug Treatment of Hypertension Complicating Diabetes Mellitus

Mary J. MacLeod* (Corresponding Author), James McLay

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hypertension and diabetes mellitus are both common conditions associated with a high morbidity and mortality. When the two conditions occur together, as they do in 50% of diabetic individuals, the result is a 7.2-fold increase in mortality. If hypertension occurs in association with diabetes mellitus and diabetic nephropathy, mortality rises to 37-fold above that of a healthy population. Despite the increase in incidence of nephropathy, cardiovascular disease remains the major cause of death in diabetic individuals. Therapy should therefore take into consideration the results of large, placebo-controlled trials which have shown reduction in cardiovascular morbidity and mortality as a result of active treatment. Although studies with the newer antihypertensive agents such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are ongoing, only diuretics and β-adrenoceptor antagonists have been clearly shown to reduce cardiovascular risk. Despite concerns regarding adverse metabolic effects and loss of hypoglycaemic awareness, β-blockers and diuretics do have a role in the management of diabetic patients. While it is clear that ACE inhibitors reduce the progression of diabetic nephropathy, evidence suggests that diuretics may be just as effective. However, unlike diuretics or β-blockers, ACE inhibitors have no proven benefit in the prevention of stroke or myocardial infarction. Despite the claims of metabolic neutrality made for many antihypertensive agents there appears to be no advantage in their use in the majority of hypertensive diabetic patients, except where there exist specific contraindications to established therapies.

Original languageEnglish
Pages (from-to)189-202
Number of pages14
JournalDrugs
Volume56
Issue number2
DOIs
Publication statusPublished - 31 Aug 1998

Fingerprint

Diuretics
Diabetes Mellitus
Angiotensin-Converting Enzyme Inhibitors
Hypertension
Mortality
Diabetic Nephropathies
Pharmaceutical Preparations
Antihypertensive Agents
Morbidity
Therapeutics
Hypoglycemic Agents
Adrenergic Receptors
Cause of Death
Cardiovascular Diseases
Stroke
Myocardial Infarction
Placebos
Calcium
Incidence
Population

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Drug Treatment of Hypertension Complicating Diabetes Mellitus. / MacLeod, Mary J. (Corresponding Author); McLay, James.

In: Drugs, Vol. 56, No. 2, 31.08.1998, p. 189-202.

Research output: Contribution to journalArticle

@article{2afd04aa8ff44a5c9c1f8b199ba59bbe,
title = "Drug Treatment of Hypertension Complicating Diabetes Mellitus",
abstract = "Hypertension and diabetes mellitus are both common conditions associated with a high morbidity and mortality. When the two conditions occur together, as they do in 50{\%} of diabetic individuals, the result is a 7.2-fold increase in mortality. If hypertension occurs in association with diabetes mellitus and diabetic nephropathy, mortality rises to 37-fold above that of a healthy population. Despite the increase in incidence of nephropathy, cardiovascular disease remains the major cause of death in diabetic individuals. Therapy should therefore take into consideration the results of large, placebo-controlled trials which have shown reduction in cardiovascular morbidity and mortality as a result of active treatment. Although studies with the newer antihypertensive agents such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are ongoing, only diuretics and β-adrenoceptor antagonists have been clearly shown to reduce cardiovascular risk. Despite concerns regarding adverse metabolic effects and loss of hypoglycaemic awareness, β-blockers and diuretics do have a role in the management of diabetic patients. While it is clear that ACE inhibitors reduce the progression of diabetic nephropathy, evidence suggests that diuretics may be just as effective. However, unlike diuretics or β-blockers, ACE inhibitors have no proven benefit in the prevention of stroke or myocardial infarction. Despite the claims of metabolic neutrality made for many antihypertensive agents there appears to be no advantage in their use in the majority of hypertensive diabetic patients, except where there exist specific contraindications to established therapies.",
author = "MacLeod, {Mary J.} and James McLay",
year = "1998",
month = "8",
day = "31",
doi = "10.2165/00003495-199856020-00003",
language = "English",
volume = "56",
pages = "189--202",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Drug Treatment of Hypertension Complicating Diabetes Mellitus

AU - MacLeod, Mary J.

AU - McLay, James

PY - 1998/8/31

Y1 - 1998/8/31

N2 - Hypertension and diabetes mellitus are both common conditions associated with a high morbidity and mortality. When the two conditions occur together, as they do in 50% of diabetic individuals, the result is a 7.2-fold increase in mortality. If hypertension occurs in association with diabetes mellitus and diabetic nephropathy, mortality rises to 37-fold above that of a healthy population. Despite the increase in incidence of nephropathy, cardiovascular disease remains the major cause of death in diabetic individuals. Therapy should therefore take into consideration the results of large, placebo-controlled trials which have shown reduction in cardiovascular morbidity and mortality as a result of active treatment. Although studies with the newer antihypertensive agents such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are ongoing, only diuretics and β-adrenoceptor antagonists have been clearly shown to reduce cardiovascular risk. Despite concerns regarding adverse metabolic effects and loss of hypoglycaemic awareness, β-blockers and diuretics do have a role in the management of diabetic patients. While it is clear that ACE inhibitors reduce the progression of diabetic nephropathy, evidence suggests that diuretics may be just as effective. However, unlike diuretics or β-blockers, ACE inhibitors have no proven benefit in the prevention of stroke or myocardial infarction. Despite the claims of metabolic neutrality made for many antihypertensive agents there appears to be no advantage in their use in the majority of hypertensive diabetic patients, except where there exist specific contraindications to established therapies.

AB - Hypertension and diabetes mellitus are both common conditions associated with a high morbidity and mortality. When the two conditions occur together, as they do in 50% of diabetic individuals, the result is a 7.2-fold increase in mortality. If hypertension occurs in association with diabetes mellitus and diabetic nephropathy, mortality rises to 37-fold above that of a healthy population. Despite the increase in incidence of nephropathy, cardiovascular disease remains the major cause of death in diabetic individuals. Therapy should therefore take into consideration the results of large, placebo-controlled trials which have shown reduction in cardiovascular morbidity and mortality as a result of active treatment. Although studies with the newer antihypertensive agents such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are ongoing, only diuretics and β-adrenoceptor antagonists have been clearly shown to reduce cardiovascular risk. Despite concerns regarding adverse metabolic effects and loss of hypoglycaemic awareness, β-blockers and diuretics do have a role in the management of diabetic patients. While it is clear that ACE inhibitors reduce the progression of diabetic nephropathy, evidence suggests that diuretics may be just as effective. However, unlike diuretics or β-blockers, ACE inhibitors have no proven benefit in the prevention of stroke or myocardial infarction. Despite the claims of metabolic neutrality made for many antihypertensive agents there appears to be no advantage in their use in the majority of hypertensive diabetic patients, except where there exist specific contraindications to established therapies.

UR - http://www.scopus.com/inward/record.url?scp=0031819648&partnerID=8YFLogxK

U2 - 10.2165/00003495-199856020-00003

DO - 10.2165/00003495-199856020-00003

M3 - Article

C2 - 9711444

AN - SCOPUS:0031819648

VL - 56

SP - 189

EP - 202

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 2

ER -